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The Papanicolaou Society of Cytopathology has developed a set of guidelines for respiratory cytology 
including indications for sputum examination, bronchial washings and brushings, CT-guided FNA and 
endobronchial ultrasound guided fine needle aspiration (EBUS-FNA), as well as recommendations for 
classification and criteria, ancillary testing and post-cytologic diagnosis management and follow-up.  All 
recommendation documents are based on the expertise of committee members, an extensive literature 
review, and feedback from presentations at national and international conferences.  The guideline 
documents selectively present the results of these discussions. 
The present document summarizes recommendations for ancillary testing of cytologic samples.  
Ancillary testing including microbiologic, immunocytochemical, flow cytometric, and molecular testing, 
including next-generation sequencing are discussed. 
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Ancillary Testing for Respiratory Cytology 
With the advent of targeted therapy for lung cancer, ancillary testing of specimens derived from the 
lower respiratory tract has obtained greater importance.  Traditionally, ancillary testing was confined to 
culture techniques for microbiologic organisms, flow cytometry for lymphoid proliferations, and 
immunohistochemical and histochemical stains to aid in classification of pulmonary neoplasms.  
Targeted therapeutic options have expanded the need for ancillary testing and in particular molecular 
testing, to document the presence or absence of clinically relevant genetic alterations that include: 
single nucleotide variants, insertion/deletions, copy number variations, and structural variants that 
indicate a carcinoma’s susceptibility to specific drug therapies (personalized medicine).   
Some of the ancillary testing methods require dedicated transfer media or special preparation methods 
for optimal test performance.  Rapid on-site evaluation (ROSE) allows intraprocedural cytologic 
evaluation with identification of the pathologic process and appropriate triage of material for specialized 
testing including microbiologic culture, flow cytometric evaluation, and molecular testing.  Transport 
media requirements for microbiologic culture have been published.
1  
Direct placement of aspirated 
material into RPMI (Roswell Park Memorial Institute) medium is a standard approach for the submission 
of a cytologic sample for flow cytometry testing.
2
  While smears, liquid based preparations, and cell 
block preparations can all be used for immunohistochemistry and most molecular testing, formalin fixed 
and paraffin embedded (FFPE) cell block material is preferred by some laboratories.
3-8
  FFPE cell block 
material is conventionally most convenient from a molecular pathology validation standpoint because 
this specimen type most closely approximates how small biopsies are processed and hence does not 
need its own validation process which can be cumbersome.  The best preparation for 
immunocytochemistry (ICC) appears to be formalin-fixed, paraffin-embedded tissue (FFPE).  A recent 
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study demonstrated problems with validation in nearly one half of antibodies tested using the Cellient 
cell block system (fixed in PreservCyt).
9 
 The antibodies had been previously validated for formalin-fixed., 
paraffin-embedded specimens.  These findings bring into question the utility of methanol-fixed material 
for ICC and the probable need for revalidation of antibodies when methanol-fixed material is used.  




The lung is a favored site for localization of a number of infectious processes.  These infectious agents 
can produce diffuse changes (lobar pneumonia) or more localized changes including abscesses and 
granuloma.  A large number of infectious agents including viruses, fungi, bacteria, and mycobacteria 
may be responsible for pulmonary disease.  Viral infections often have characteristic cytopathic effects 
facilitating their recognition.  While viruses are rarely investigated by culture methods, other infectious 
agents are best definitively identified by a variety of culture techniques. 
Culture of pulmonary specimens represents an important component of examination for many sputum, 
bronchoalveolar lavage and fine needle aspiration (FNA) specimens.  Culture for acid fast bacilli, fungi 
and bacteria is often the most sensitive technique for establishing a specific diagnosis.  Successful 
culture of a number of organisms requires specialized techniques and media.  Optimal transport media 
have been identified for lymph node aspirates
1
 and similar techniques and media can be used for 
pulmonary FNA specimens.  ROSE examination may be helpful in selecting if and in what media material 
should be sent for culture.   
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Recommendation 1: Cytologic specimens from lesions suspected to be of infectious etiology should be 
sent for culture in appropriate transport media.  Rapid on-site evaluation may be helpful in selecting the 
appropriate culture techniques. 
Immunocytochemistry 
Immunocyto hemistry is an important diagnostic technique for the identification and classification of 
metastatic disease.  The separation of primary adenocarcinoma from squamous cell carcinomas and the 
identification of small and large cell neuroendocrine carcinomas and carcinoid tumors may be facilitated 
by immunocytochemistry.   
With the development of targeted therapy for pulmonary adenocarcinomas, the separation of 
adenocarcinomas from squamous cell carcinoma has become critically important.
10
 Panels of antibodies 
have been found useful for this distinction.  Immunohistochemistry is also of aid in determining the 
primary site of origin for metastatic disease.  The use of differential cytokeratin staining and direction of 
differentiation markers can be particularly helpful in establishing the site of origin for a metastatic 
neoplasm.  Finally, immunocytochemistry can be used for prediction of response to tyrosine kinase 
inhibitors and to identify targets for immunotherapy such as PD-L1. 
Immunochemistry is important in the evaluation of neuroendocrine tumors.  The World Health 
Organization guidelines require evaluation of Ki-67 index for classification of these neoplasms.
11
  




Antibodies Useful In Separating Pulmonary Adenocarcinomas from Squamous Cell Carcinomas 
CK5/6, TTF-1, napsin A, p63, and p40 have been identified as helpful for separating pulmonary 
adenocarcinoma from squamous cell carcinoma.
10, 14-24
  These antibodies can be used on smears, liquid 
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based preparations, and formalin-fixed paraffin embedded cell block material.  A recent study has 
questioned the reliability of the use of immunocytochemistry on methanol-fixed cell block material.
9 
TTF-1 reacts with cells differentiating towards follicular thyroid epithelium,
25
 some gastric 
adenocarcinomas,
26 
and some pulmonary adenocarcinomas and small cell carcinomas.
27,28
  The 
sensitivity and specificity of TTF-1 for the separation of pulmonary adenocarcinoma from squamous cell 




 respectively.   
Napsin A has been shown to be reactive with pulmonary epithelium
20
 and some neoplasms arising 
primarily within the ovary and other sites.
30
 The sensitivity and specificity for napsin A in separating 
pulmonary adenocarcinomas from squamous cell carcinomas are 85% and 94% respectively.
17
 
p63 is a marker helpful in distinguishing squamous cell carcinomas from adenocarcinoma.
29,31
  While p63 
is reactive in up to one third of pulmonary adenocarcinomas,
10 
it remains useful for separating 
squamous carcinomas with a sensitivity and specificity of 100% and 85% respectively for the recognition 
of squamous cell carincoma.
31
  
p40 appears more specific for squamous cell carcinomas than p63 and some authors have advocated its 
replacing p63.
10
  p40 has a sensitivity of 94% and a specificity of 96% for squamous cell carincoma.
29
 
Other authors have also found p40 to be superior to p63 for the identification of squamous cell 
carcinomas of the lung.
32-34 
A number of authors have recommended panels of two to four immunohistochemical markers for the 
distinction of pulmonary adenocarcinoma from squamous cell carcinoma of the lung.
29,31-36
  Potential 
panels include, (i) TTF-1, napsin A, p63, CK 5/6; (ii)TTF-1 and p40; (iii) napsin A and p40; or (iv)TTF-1 and 
p63.  When performing immunohistochemistry for distinction of adenocarcinoma from squamous cell 
carcinoma it should be kept in mind that adequate material must be preserved for molecular testing.  
Core biopsy should be encouraged for back-up, especially when ROSE shows that the sample cellularity 
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might be too low for analysis.
34
 Kimbrell et al
37
 addressed the issues concerning the utilization of 
immunocytochemistry in the sub-classification of non-small cell lung carcinomas. 
Because diagnostic material must be saved for molecular testing, the use of double staining techniques 
should be considered when using immunocytochemistry for distinguishing squamous from 
adenocarcinomas.  Johnson et al
38
 has described a double staining method for TTF-1 and Napsin A. 
 
Recommendation 2: 
Pulmonary adenocarcinomas should be distinguished from squamous cell carcinomas.  Use of 
immunohistochemical panels including some combination of TTF-1, napsin A, p63, p40 and CK 5/6 is 
recommended when significant cellular differentiation such as distinct keratinization is not seen.  To 
preserve tissue for subsequent molecular testing, preferably one marker of adenocarcinoma and one of 
squamous cell carcinoma should be selected.  Excessive immunostaining should be avoided to ensure 
preservation of cellular material for requested or anticipated molecular testing.  The combination of 
TTF-1 and p40 appears optimal for separation of adenocarcinomas form squamous cell carcinoma. 
Immunocytochemistry for Molecular Predictive Markers 
While predictive testing for susceptibility to tyrosine kinase inhibitors is generally performed by 
molecular methods (FISH or PCR-based techniques), immunocytochemical methods exist for testing of 
some predictive markers.  Immunocytochemical techniques have been used as initial tests which when 
positive, the specimen can be reflexed to a molecular laboratory for confirmatory testing.  Antibodies 
directed against rearranged ALK,
39-41
 ROS1, and mutated EGFR
42,43 
are three such markers.  However, the 
utility of this approach may be limited.  Antibodies directed against mutated EGFR are limited to 
detecting specific mutations (15 base pair deletions in exon 19 and p.L858R mutation in exon 21) and fail 
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to detect other EGFR mutations; while the ALK antibody may have false positive and false negative 
results.
43-46
  Immunohistochemistry appears to be a useful screening technique for ALK rearrangements 
with subsequent reflex of positive results to FISH analysis.  This approach using reflex testing reduces 
overall cost as the percentage of pulmonary adenocarcinomas with ALK alterations is low.  Currently, the 
Food and Drug Administration (FDA) approved immunohistochemical method assessing ALK status uses 
the D5F3 antibody (Cell Signaling) with testing performed on the BenchMark XT instrument.  This 
antibody detects expressed endogenous levels of total ALK protein (when present).   Other antibody 
clones have been developed and are in clinical use. 
Currently, immunohistochemistry may be a cost reduction technique for identification of molecular 
aberrations that occur at low frequency such as ROS1.  A number of antibodies have been developed 
against ROS1 and detect the inappropriately expressed endogenous protein.  Such inappropriate 
expression of the endogenous protein has been shown to occur in approximately 1.6% of non-small cell 
carcinomas of the lung.
47
  Antibodies raised against ROS1 protein may represent a useful screening 




Immunocytochemical testing for mutated EGFR is not the preferred testing method for determination of 
tumor susceptibility to the associated tyrosine kinase inhibitors, but may be utilized in the setting of a 
limited volume sample when molecular testing cannot be performed. 
Immunocytochemical testing for rearranged ALK may be used in place of FISH testing. 
 
PD-L1 Immunocytochemical Testing 
Page 9 of 30
John Wiley & Sons
Diagnostic Cytopathology












Expression of Programmed Death Ligand-1 (PD-L1) is a predictive marker for anti-PD-1/PD-L1 therapies.  
PD-L1 is sometimes expressed in large amounts on cancer cells and allows their escape from immune 
surveillance and immune destruction.
49,50  
A new class of drugs target PD-1 or PD-L1 and are reported to 
have activity against some malignancies including non-small cell lung cancers.
51,52
  These drugs are useful 
for treatment of patients when standard chemotherapy has become ineffective.  Nivolumab and 
pembrolizumab have been approved for treatment of non-small cell lung cancer, including both 
squamous cell carcinoma and adenocarcinoma.  Section of the appropriate antibody clone for prediction 






Immunohistochemical testing for anti PD-1/PD-L1 therapy appears appropriate for some patients who 
have become refractory to standard chemotherapy regiments.  Selection of the antibody used for 
testing depends on the specific anti PD-1/PD-L1 drug used.  Immunocytochemical testing for PD-L1 in 
non-squamous, non-small cell pulmonary carcinomas may aid in the selection of targeted therapy.  
Detection of PD-L1 expressing carcinoma cells may indicate improved survival when patients are treated 
with Nivolumab therapy.
53
  PD-L1 testing of cytology specimens has not undergone extensive validation 
in the published literature and specific recommendations fo its use for cytology material cannot be 
made at this time. 
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PD-1/PD-L1 testing is performed at the discretion of the local oncology team and may be especially 
useful for patients non-responsive to tyrosine kinase inhibitor therapies.  Treatment of squamous cell 
carcinoma with Nivolumab can be done without PD-L1 testing. 
 
Immunocytochemical Testing for c-MET 
Mesenchymal-epidermal transition (MET) receptor tyrosine kinase has been identified as a potential 
target for the treatment of non-small cell
54,55 
and some drug resistant small cell lung cancers.
56
  c-MET 
overexpression may be important in the development of resistance to EGFR-tyrosine kinase inhibitors
54
 
and some chemotherapeutic agents used for treatment of small cell lung cancer.
56
  MET amplification 
occurs in up to 20% of non-small cell carcinomas refractory to EGFR-tyrosine kinase therapy and some 
studies have suggested utility for the combined use of drugs resulting in MET and EGFR co-inhibition.
54
  
The role of immunohistochemistry for the prediction of response of c-MET inhibitors has not yet been 
elucidated, but c-MET therapy based on immunohistochemical staining has shown promise.
57
  MET 
testing may have potential value for predicting progression on targeted therapy (EGFR) but such testing 
is for MET amplification and is performed by FISH. 
 
Recommendation 5: 
Currently, MET testing cannot be recommended for routine use, but such testing can be performed at 
the discretion of the local oncology team. 
 
Immunocytochemistry for the Identification and Classification of Metastatic Malignancies to the Lung 
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Metastatic disease is responsible for a significant percentage of lung nodules.  While negative results of 
markers such as napsin A and TTF-1 may suggest a non-primary pulmonary adenocarcinoma, lack of 
staining for these markers does not exclude a lung origin, particularly in mucinous adenocarcinoma. A 
combination of cytomorphologic features and immunohistochemical reaction patterns is used to 
diagnose metastatic neoplasms.  Differential cytokeratin staining patterns (CK7, CK20, and CK5/6) and 
specific lineage markers such as melan-A, HMB-45, prostatic specific antigen (PSA), leukocyte common 
antigen (LCA), p40, CDX-2, GATA-3, PAX-8, desmin, muscle specific actin (MSA), smooth muscle actin 
(SMA) and CD117 among others can be extremely helpful in the specific diagnosis of a metastatic 
neoplasm.  Table I lists a selection of immunocytochemical markers helpful in the evaluation of 
metastatic neoplasms.  Immunocytochemical testing of samples to determine tumor type or site of 
origin for metastases is a complex process with overlapping patterns of staining between pulmonary 
primaries and metastatic disease.  For instance, some pulmonary adenocarcinomas may be CK20 
positive (a finding often considered supporting a non-pulmonary origin).  Similarly, CDX-2 a marker 
considered to support a gastrointestinal origin may be positive in some mucinous carcinomas of the 
lung.  GATA-3, which usually supports a urothelial origin, may be expressed by some pulmonary 
squamous cell carcinomas.  Thus, no single immunocytochemical staining result is definitively diagnostic 




Selected panels of antibodies should be used to establish the origin and direction of differentiation in 
suspected metastatic disease to the lung.  The precise panel of antibodies should be determined by 
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morphologic analysis of cytologic specimen and review of the patient’s medical history and imaging 
findings. 
 
Molecular Techniques for Predictive Testing Associated with Targeted Therapy 
The advent of a number of targeted therapies for lung cancer has placed new responsibilities on 
pathologists to perform molecular studies used to identify patients likely to respond to such therapies.  
Not only is the pathologist responsible for identifying which carcinomas should undergo testing, but 
he/she is responsible to ensure that adequate and representative material is present for ancillary 
testing.  Presently, the majority of such targeted therapies are directed at adenocarcinomas (EGFR, ALK, 
and ROS1), but new therapies targeting squamous cell carcinomas are under development.  The 
pathologist must make every attempt possible to obtain adequate tissue for molecular testing.
58,59
  
Proper tissue acquisition and management requires good communication between pulmonologist, 
radiologist and pathologist.
10
  ROSE can be very helpful in assuring adequate tissue is collected when 
sampling is performed under endobronchial ultrasound (EBUS) or computerized tomography (CT) 
guidance.  Since EGFR, KRAS, ROS1, and ALK testing can be reliably performed on formalin fixed paraffin 
embedded cell block material,
10,60-63
 ROSE can be very useful in triaging material for processing to cell 
block.
63 
The choice of the appropriate specimen type for molecular testing remains controversial.  
Studies have demonstrated that formalin fixed paraffin embedded cell block (CB) material is a 
satisfactory substrate for molecular testing
64
 but cellularity of CBs remains a problem with up to 57% of 
CBs being acellular or of borderline cellularity for molecular testing.
65
  Most studies have reported on 
the utility of formalin-sixed, paraffin-embedded surgical resection specimens or small biopsy specimens, 
but a number of studies have addressed the use of cytologic preparations.
66,67
  These studies reviewed 
the use of CBs, direct smears, and liquid based preparations.  Current data indicates that a variety of 
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cytologic preparations yield molecular testing results similar to those achieved with histologic 
samples.
67-70
  In some cases, cytologic samples have been associated with detection rates for mutations 
higher than those obtained by histologic sampling methods.
70
  Cell blocks have been shown to be 
comparable to core biopsies in some studies for detection of clinically important mutations.
71,72
  A 
significant number of studies have shown that smears and CBs are equivalent for molecular testing.
68,73-
75
  In an analysis of 181 articles focusing on EGFR analysis in lung cancer, da Cunha Santos et al.
66
 showed 
that cytologic techniques using an array of fixation and processing techniques yielded mutation 
detection rates similar if not superior to histologic material.  Moreover, cell blocks, smears, and liquid 
based techniques were all useful for detection of clinically important mutations in non-small cell lung 
cancer.
66 
The majority of organizations and authors recommend molecular testing of pulmonary adenocarcinoma 
for EGFR and ALK.
75,76
  In general, when tissue is limited, EGFR testing is prioritized and performed 
before ALK.
63,75
  Additional markers that may be tested in pulmonary adenocarcinomas include KRAS, 
ROS1, BRAF, RET, MET, neurotrophic tyrosine kinase receptor type 1 (NTRK1) and v-erb-b2 
erythroblastic leukemia viral oncogene homolog2 (ERBB2).
76,77
  While no recommendations for 
prioritization of these markers have yet been published, some authorities recommend early 
performance of KRAS analysis.  KRAS mutations appear to exclude mutations in EGFR and EML4-ALK and 
the KRAS gene product is present in the control pathway before EGFR and EML4-ALK, thus negating the 
impact of these latter two genes.  With the recent FDA approval of crizotinib for treatment of ROS1 
rearranged tumors, immunocytochemical or FISH testing for ROS1 rearrangements should now be 
performed following negative results for EGFR and ALK testing. 
Molecular testing for pulmonary squamous cell carcinoma remains in its infancy with few markers yet 
having clinical utility.  Potential target genes include: fibroblast growth factor receptor 1 (FGFR1) and the 
related amplification in FGFR2, FGFR3, and FGFR4.
78
  Other potential targets are phosphatase and tensin 
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homolog (PTEN), platelet-derived growth factor receptor alpha (PDGFRA) and discoidin domain-
containing receptor 2 (DDR2).
76,78 
 
EGFR Testing For Pulmonary Adenocarcinoma 
EGFR mutation testing should be performed at time of diagnosis for patients presenting with high stage 
disease (stage III and higher).
75
  Patients should not be excluded from such testing based solely on 
clinical features.  Lower stage patients may be tested at time of recurrence or progression.  Retesting of 
EGFR should be considered when new recurrences or metastases are detected to look for new 
mutations.  Patients stage I, II, or III may be tested at the discretion of the local oncology team.  Results 
of testing should be available within 10 working days.
75
 
EGFR testing can be performed on formalin-fixed paraffin-embedded (FFPE) material (cell block/core 
biopsy), fresh, frozen, air dried smears, or alcohol fixed specimens for polymerase chain reaction (PCR) 
based testing.
67-72
  While FFPE material is one of the most common sources of material for molecular 
analysis in many laboratories,
75,79
 recent studies have shown that material obtained from air-dried and 
alcohol-fixed cytologic smears can be reliably used.
62,63,76,77
  Sample adequacy for analysis should be 
confirmed by a pathologist.  While specimens with 20% or greater cancer cells are prefered,
63
 many 
laboratories have reported successful results using significantly lower concentration of cancer cells, 
provided the sample meets the analytic sensitivity of the platform used and with appropriate validation 
studies.  The testing method should be able to detect mutations in EGFR exons 18, 19, 20 and 21
75
 as the 
two most commonly observed EGFR mutations in pulmonary adenocarcinomas are the p.L858R 
substitutions and small frame deletions in exon19.
76
  Currently immunohistochemistry is not 
recommended for selection of EGFR based therapy. 
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KRAS Testing For Pulmonary Adenocarcinoma 
KRAS mutational analysis may be helpful in therapy selection, but it should not be the sole method for 
EGFR therapy selection.  KRAS codon 12, 13, 61, and 146 mutations can be tested for by PCR-based 
techniques and when present are thought to exclude mutations in EGFR and ALK rearrangements.  
Moreover, patients with KRAS mutations may have poor responses to both EGFR based therapy and 
more traditional chemotherapy justifying to some oncologists, the need for early KRAS testing.  The 
predictive value of KRAS testing for response to anti-EGFR based therapy remains controversial.  Some 
recent data indicates that up to 3% of patients with KRAS mutations will respond to anti-EGFR therapy.
80
  
This finding brings into question KRAS testing as a guide for response to anti-EGFR therapy. 
 
 
ALK Rearrangement Testing for Pulmonary Adenocarcinoma 
ALK rearrangement testing should be performed on all high stage lung adenocarcinomas at time of 
diagnosis and on lower stage patients at time of recurrence or progression.  Testing may be performed 
on FFPE material, but can also be performed on smears.  In general, the slide should contain 50 cancer 
cells suitable for evaluation.  When material is insufficient for both EGFR and ALK rearrangement testing 
EGFR testing has priority.  The FISH method appears optimal for ALK rearrangement testing.
41
  Screening 
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EGFR mutation testing should be performed at time of diagnosis for patients presenting with high stage 
disease.  Testing of stage I, II and III patients may be performed at the discretion of the local oncology 
team.  Reflex testing to ALK should be performed when EGFR mutational analysis is negative.  Cell block 
and smears can be used for testing following appropriate validation of this specimen type. 
 
Recommendation 8: 
KRAS testing remains controversial and may be performed on pulmonary non-small-cell carcinomas at 
the discretion of the local oncology team. 
 
 
ROS1 Testing for Primary Pulmonary Adenocarcinoma 
ROS1 is a receptor tyrosine kinase phylogenetically related to ALK.
81,82
  ROS1 rearrangements are seen in 
1 to 2.5% of non-small cell carincoma
83,84 
and are mutually exclusive with other tyrosine kinase genetic 
abnormalities.  Patients with ROS1 rearrangments appear to benefit from crizotinib therapy.
85
  Since 
ROS1 rearranged pulmonary adenocarcinomas are rare,  only patients lacking changes in EGFR, KRAS,  




FISH testing for ROS1 rearrangements may be performed at the discretion of the local oncology team in 
high stage pulmonary adenocarcinomas who have been shown to lack molecular/genetic changes in 
EGFR, ALK, and KRAS.  Immunocytochemical testing for ROS1 can be an acceptable alternative to FISH. 
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Next-Generation Sequencing and Molecular Analysis of Pulmonary Carcinoma 
In an era of precision medicine with new emerging biomarkers guiding therapeutic decisions in lung 
cancer, there is an increasing need for a more comprehensive approach to generate a complete 
molecular profile for cytologic specimens.  Clinical next-generation sequencing (NGS) has allowed for 
simultaneous screening of multiple genes in a massively parallel manner from cytologic samples using 
very small amounts of DNA.  Several recent studies have described the utility of NGS mutational analysis 
in pulmonary cytopathology utilizing both aspiration cytology (CT-guided FNA and EBUS-guided FNA)
86-90
 
as well as exfoliative cytology (body cavity fluids and bronchoalveolar lavage) specimens.
89,91,92
  The high 
analytical sensitivity of NGS platforms (approximately 5-10%) permits evaluation of samples with 
relatively low tumor fraction.
87,91,93,94
  One of the earlier studies utilizing NGS on cytologic specimens 
demonstrated the high sensitivity of NGS compared to conventional testing methods by using cells 
extracted from Papanicolaou stained smears of low tumor volume samples of bronchoalveolar lavage 
and pleural fluids.
91
  NGS success rates do not vary significantly between aspiration and exfoliative 
cytology samples and NGS success rates of lung FNAs are similar to that of other sites.
89
  
The most common causes of NGS failure in lung cytologic specimens are related to insufficient DNA 
yield, due to overall low cellularity, or insufficient tumor cellularity, in cases with high numbers of non-
tumor background cells and/or where the tumor cells are heterogeneously distributed, frequently seen 
in EBUS FNA, samples obtained by brushing, or body cavity fluid samples.
88
  Although aspiration cytology 
specimens usually provide inherently high tumor fraction due to lower numbers of background stromal 
components, they are frequently limited by the volume of tissue aspirated (overall cellularity) that 
dictates the quantitative DNA yield.
89,93
  Implementing measures such as ROSE for adequacy assessment 
and additional needle passes may improve the overall cellularity to meet the input DNA requirement for 
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 Also, tumor enrichment techniques by demarcating on the H&E stained cell block 
section or directly on the smear slides for macro/microdissection can improve the tumor fraction by 
eliminating background non-tumor cells, thereby reducing the chances of a false negative result.
96 
Cell block preparations as well as direct smears and liquid-based cytology (LBC) have been successfully 
employed for NGS.
86-90,92  
The input DNA requirement for NGS analysis varies by testing platform but 
ranges between 10 ng for Ion Torrent PGM (Life Technologies, Carlsbad, CA) and 250 ng for Illumina 
(Illumina Inc, San Diego, CA) platforms.
97
  Depending on the target capture method and the platform 
type, this roughly translates to approximately 100 to 1000 cells for Ion Torrent and 5000-15,000 cells for 
Illumina NGS.
98
  There is no significant difference in NGS success rates between specimen preparations 
or cytological stains/fixatives.
88
  The NGS sequencing performance metric (coverage depth, total number 
of reads, number of mapped reads and on-target reads, and variant calls) of cytologic smears and cell 
block preparations are comparable to that of FFPE histologic specimens.
88,90
  In addition, NGS has been 
successfully performed using DNA extracted from residual LBC samples of FNA and body fluid samples 
with significantly higher DNA yield from the LBC rinse than the matched cell block sections.
92
  
Molecular diagnostics in lung cytopathology has undergone a paradigm shift with the advent of NGS 
which allows for evaluation of multiple biomarkers in a single assay using minimal amounts of DNA.
97-99
  
In this changing landscape of precision medicine, the cytopathologist plays a critical role in triaging and 
selecting suitable material for successful implementation of NGS on lung cytologic specimens.  However, 
one needs to keep in mind that NGS not only detects known driver mutations for specific targeted 
therapy, but will likely also identify passenger mutations and/or low level mutations in small subclonal 
populations, and variants of unknown significance (VUS), all of which need to be interpreted in the 
proper clinical context for subsequent clinical management.  In the absence of “actionable” oncogenic 
mutations, these may have some relevance in the prospective enrollment of patients in pre-clinical or 
clinical trials for targeted therapy.
100,101
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Table I. Useful Immunohistochemical Markers for Identification of Unknown Primaries 
Organ Immunohistochemical Marker 
Adrenocortical Inhibin, MelanA, Ad4BP 
Adrenomedullary NSE, synaptophysin, chromogranin, PGP9.5 
Biliary CK7, CDX-2, CK19, CEA, MOC-31 
Breast ER, PR, GATA-3, CK7, CEA 
Cervix (adenocarcinoma) CEA, CK7, p16 
Cervix (squamous cell) CK7, p16 
Colon CK20, villin 
Esophagus (adenocarcinoma) MUC5AC, MUC4, CA19-9, CEA, EMA 
Esophagus (squamous cell) AE1/3, CK5/6, p63, CK19 
Endometirum CK7, vimentin, ER, p53, inhibin, EMA 
Gastric (adenocarcinoma) EMA, MUC5AC, MUC4, BerEP4, CA19-9, CEA 
Germ Cell Tumor CD30, hCG, Oct4, CK, AFP, Glypican 3, CD117, PLAP, WT-1, CD10, EMA 
Hepatocellular EMA, Hep Par-1, CEA 
Kidney EMA, CD10, vimentin, RCC 
Lung (adenocarcinoma) CK7, TTF-1, Napsin, villin 
Lung (squamous cell) p63, p40 
Lung (small cell) CK7, chromogranin, synaptophysin 
Ovary (mucinous) CK7, CK20 
Ovary (serous) CK7, WT-1 
Pancreas (ductal) CK7, CK20 
Pancreas (neuroendocrine) CK7, CK20, chromogranin, synaptophysin 
Prostate PSA, PAP 
Salivary Gland GFAP, s-100 protein, c-kit, Bcl-2, CK7 
Thymus CD5 (Thymic carcinoma) 
Thyroid TTF-1, Thyroglobulin, CK19 (papillary), HBME-1 (papillary), galectin-3 
(papillary), calcitonin (medullary) 
Urothelium (bladder) CK7, CK20, p63, Thrombomodulin, GATA-3 
Mesothelioma Mesothelin, CK7, WT-1, calretinin, CK5/6, D2-40 
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